| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| MK-0482 | MK-0482 | Phase 2 Clinical | Merck Sharp & Dohme Corp | Carcinoma, Non-Small-Cell Lung; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Neoplasms; Sarcoma; Squamous Cell Carcinoma of Head and Neck | Details |
| IO-202 | IO-202 | Phase 1 Clinical | Yiming Biomedical Technology (Hangzhou) Co Ltd | Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Solid tumours | Details |
| anti-ILT3 CAR T-cell therapy (Carbiogene Therapeutics) | Phase 1 Clinical | Carbiogene Therapeutics Co Ltd | Leukemia, Myeloid, Acute | Details | |
| YTS-104 | LILRB4 STAR-T; YTS-104 | Phase 1 Clinical | Beijing Qingyi Taike Pharmaceutical Technology Co Ltd, China Immunotech Co Ltd | Leukemia, Myeloid | Details |
| BND-35 | BND-35; BND35 | Phase 1 Clinical | Biond Biologics Ltd | Neoplasms; Solid tumours | Details |
| NGM-831 | NGM-831 | Phase 1 Clinical | NGM Biopharmaceuticals Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Mesothelioma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uterine Cervical Neoplasms | Details |
| anti-ILT3 CAR-T Therapy(Carbiogene) | Phase 1 Clinical | Carbiogene Therapeutics Co Ltd | Leukemia, Myeloid, Acute | Details |